Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma.

Doyle SP, Gurbani SS, Ross AS, Rosen H, Barrett CD, Olson JJ, Shim H, Shu HK, Sengupta S.

Oxf Med Case Reports. 2018 Nov 5;2018(12):omy095. doi: 10.1093/omcr/omy095. eCollection 2018 Dec.

2.

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.

Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, Suh JH, Toms SA, Vogelbaum MA, Weil RJ, Elson P, Barnett GH.

J Neurooncol. 2010 May;98(1):93-9. doi: 10.1007/s11060-009-0067-2. Epub 2009 Dec 4.

PMID:
19960228
3.

Alternating Electric Fields (“Tumour-Treating Fields”) for the Treatment of Glioblastoma.

Topfer LA, Farrah K.

CADTH Issues in Emerging Health Technologies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016-. 165.

4.

Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.

Zhai Y, Hui Z, Wang J, Zou S, Liang J, Wang X, Lv J, Chen B, Zhu H, Wang L.

Dis Esophagus. 2013 Jul;26(5):503-9. doi: 10.1111/j.1442-2050.2012.01380.x. Epub 2012 Aug 2.

PMID:
22862289
5.

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C, Buckner JC; North Central Cancer Treatment Group Study N0177.

J Clin Oncol. 2008 Dec 1;26(34):5603-9. doi: 10.1200/JCO.2008.18.0612. Epub 2008 Oct 27.

6.

First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report.

O'Connell D, Shen V, Loudon W, Bota DA.

CNS Oncol. 2017 Jan;6(1):11-18. doi: 10.2217/cns-2016-0018. Epub 2016 Dec 5.

7.

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA.

J Clin Oncol. 2009 Feb 1;27(4):579-84. doi: 10.1200/JCO.2008.18.9639. Epub 2008 Dec 15.

8.

A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.

Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD.

Neuro Oncol. 2014 Jul;16(7):984-90.

9.

Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.

Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, Delfini R.

Tumori. 2007 May-Jun;93(3):248-56.

PMID:
17679459
10.

Stability of Programmable Shunt Valve Settings with Simultaneous Use of the Optune Transducer Array: A Case Report.

Chan AK, Birk HS, Winkler EA, Viner JA, Taylor JW, McDermott MW.

Cureus. 2016 Jul 7;8(7):e675. doi: 10.7759/cureus.675.

11.

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.

Hainsworth JD, Ervin T, Friedman E, Priego V, Murphy PB, Clark BL, Lamar RE.

Cancer. 2010 Aug 1;116(15):3663-9. doi: 10.1002/cncr.25275.

12.

Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.

Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC.

J Clin Oncol. 2008 Oct 20;26(30):4921-7. doi: 10.1200/JCO.2007.15.2306. Epub 2008 Sep 15.

13.

Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.

Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, Simon M, Westphal M, Schackert G, Tonn JC, von Deimling A, Davis T, Weiss WA, Loeffler M, Reifenberger G; German Glioma Network.

Int J Cancer. 2014 May 15;134(10):2437-47. Erratum in: Int J Cancer. 2016 Aug 15;139(4):E9.

14.

Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.

D'Alessandris QG, Montano N, Cenci T, Martini M, Lauretti L, Bianchi F, Larocca LM, Maira G, Fernandez E, Pallini R.

Acta Neurochir (Wien). 2013 Jan;155(1):33-40. doi: 10.1007/s00701-012-1536-5. Epub 2012 Nov 8.

PMID:
23132371
15.

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.

Iwai T, Moriya Y, Shirane M, Fujimoto-Ouchi K, Mori K.

Oncol Rep. 2012 Apr;27(4):923-8. doi: 10.3892/or.2011.1614. Epub 2011 Dec 30.

16.

Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.

Zhao Q, Kretschmer N, Bauer R, Efferth T.

Int J Cancer. 2015 Sep 15;137(6):1446-56. doi: 10.1002/ijc.29483. Epub 2015 Mar 6.

17.

Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.

Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R; Head and Neck Cancer Disease Site Group.

Curr Oncol. 2010 Jun;17(3):37-48.

18.

What next for newly diagnosed glioblastoma?

Domingo-Musibay E, Galanis E.

Future Oncol. 2015;11(24):3273-83. doi: 10.2217/fon.15.258. Epub 2015 Nov 12. Review.

19.

Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide.

Robins HI, Nguyen HN, Field A, Howard S, Salamat S, Deming DA.

Front Oncol. 2018 Oct 15;8:451. doi: 10.3389/fonc.2018.00451. eCollection 2018.

20.

Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.

Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY.

Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):85-90. doi: 10.1016/j.ijrobp.2009.07.1741. Epub 2010 Feb 4.

PMID:
20137866

Supplemental Content

Support Center